suven life sciences
Jump to
235 Results Found
  • Suven Life Sci Consolidated March 2021 Net Sales at Rs 1.56 crore, down 82.02% Y-o-Y May 04, 2021 03:20 PM IST

    Suven Life Sci Consolidated March 2021 Net Sales at Rs 1.56 crore, down 82.02% Y-o-Y

  • Suven Life Sci Standalone March 2021 Net Sales at Rs 1.56 crore, down 82.02% Y-o-Y May 04, 2021 03:03 PM IST

    Suven Life Sci Standalone March 2021 Net Sales at Rs 1.56 crore, down 82.02% Y-o-Y

  • Suven Life Sci Standalone December 2020 Net Sales at Rs 1.51 crore, down 45.43% Y-o-Y Jan 29, 2021 09:11 AM IST

    Suven Life Sci Standalone December 2020 Net Sales at Rs 1.51 crore, down 45.43% Y-o-Y

  • Suven Life Sci Standalone September 2020 Net Sales at Rs 8.98 crore, up 547.27% Y-o-Y Oct 29, 2020 09:44 AM IST

    Suven Life Sci Standalone September 2020 Net Sales at Rs 8.98 crore, up 547.27% Y-o-Y

  • Suven Life Sci Standalone September 2020 Net Sales at Rs 8.98 crore, up 547.27% Y-o-Y Oct 27, 2020 06:33 PM IST

    Suven Life Sci Standalone September 2020 Net Sales at Rs 8.98 crore, up 547.27% Y-o-Y

  • Promoter Epsilon Bidco offloads 23% stake in Essel Propack, US-based Vanguard Group acquires stake in 13 firms Sep 18, 2020 10:46 PM IST

    Promoter Epsilon Bidco offloads 23% stake in Essel Propack, US-based Vanguard Group acquires stake in 13 firms

    EQ India Fund acquired 8,88,888 shares in Gati (representing 0.7 percent of its total paid-up equity) at Rs 49.45 per share on the NSE. Katkar Sanjay bought 6,88,893 equity shares in Suven Life Sciences at Rs 56.27 per share.

  • Suven Life Sci Standalone June 2020 Net Sales at Rs 1.43 crore, down 99.28% Y-o-Y Aug 11, 2020 05:00 PM IST

    Suven Life Sci Standalone June 2020 Net Sales at Rs 1.43 crore, down 99.28% Y-o-Y

  • Exclusive: Suven Life Sciences evaluating sale of demerged CRAMS arm, engages Barclays as sale adviser Feb 12, 2020 10:41 AM IST

    Exclusive: Suven Life Sciences evaluating sale of demerged CRAMS arm, engages Barclays as sale adviser

    According to its 2019 annual report, Suven Life Sciences posted total revenues of around Rs 688 crores and a net profit of around Rs 150 crores.

  • Suven Life Sciences shares trade ex-demerger, record date on Jan 22 Jan 21, 2020 04:10 PM IST

    Suven Life Sciences shares trade ex-demerger, record date on Jan 22

    The record date for demerger is January 22, which means the person has to have Suven Life's shares in his/her account by end of this day and then he/she will be eligible for shares of CRAMs business.

  • Suven Life Sciences share price rises 3% on NCLT nod for Scheme of Arrangement Jan 07, 2020 04:36 PM IST

    Suven Life Sciences share price rises 3% on NCLT nod for Scheme of Arrangement

    The contract research and manufacturing services undertaking (including its respective assets and liabilities) of the company will be transferred to Suven Pharmaceuticals by way of demerger.

  • Buy Suven Life Sciences with target Rs 387: AnandRathi Dec 02, 2019 11:05 AM IST

    Buy Suven Life Sciences with target Rs 387: AnandRathi

    Considering the lower-than-anticipated R&D cost and operating expenses, we raise our FY20e and FY21e EBITDA respectively 16.7% and 22.8%.

  • Suven Life share price plunges 19% after Alzheimer molecule disappoints in Phase 2 Dec 02, 2019 10:03 AM IST

    Suven Life share price plunges 19% after Alzheimer molecule disappoints in Phase 2

    The triple therapy of Masupirdine (SUVN-502) with Donepezil and Memantine proof of concept phase 2 study missed its pre-specified primary endpoint.

  • Suven's Alzheimer's molecule fails to meet primary end point in phase-2 trial Dec 01, 2019 08:57 AM IST

    Suven's Alzheimer's molecule fails to meet primary end point in phase-2 trial

    SUVN-502's clinical trial data assumed significance as no new Alzheimer's drug has been approved since Forest Labs' Namenda in 2003

  • Suven Life Sciences share price jumps 4% Nov 22, 2019 11:43 AM IST

    Suven Life Sciences share price jumps 4%

    The company says the phase 2 data for its SUVN 502, a drug for Alzheimer’s disease, will be out in a week.

  • Suven Life, FACT, HIL, Maharashtra Seamless share price rally 9-14% after healthy Q2 earnings Nov 14, 2019 02:36 PM IST

    Suven Life, FACT, HIL, Maharashtra Seamless share price rally 9-14% after healthy Q2 earnings

    Building material solutions provider HIL's Q2FY20 consolidated profit increased by 164 percent YoY to Rs 31.9 crore and revenue jumped 41.9 percent to Rs 585.9 crore compared to year-ago.

  • Suven Life gains 2% after CRISIL assigns 'A' rating to co's long-term bank facilities Oct 17, 2019 09:48 AM IST

    Suven Life gains 2% after CRISIL assigns 'A' rating to co's long-term bank facilities

    CRISIL assigned 'A' rating to company's long-term bank facilities and placed on ‘Rating Watch with Positive Implications'.

  • Buy Suven Life Sciences, target Rs 300: Anand Rathi Aug 26, 2019 12:32 PM IST

    Buy Suven Life Sciences, target Rs 300: Anand Rathi

    We raise our FY20 and FY21 estimates: of FY20 revenues 5 percent and FY21, 6 percent, and earnings 8 percent each, said research firm Anand Rathi.

  • Accumulate Suven Life Sciences; target of Rs 310: Dolat Capital Jun 13, 2019 01:50 PM IST

    Accumulate Suven Life Sciences; target of Rs 310: Dolat Capital

    Dolat Capital recommended Accumulate rating on Suven Life Sciences with a target price of Rs 310 in its research report dated May 28, 2019.

  • Suven Life Sci Standalone March 2019 Net Sales at Rs 253.30 crore, up 18.52% Y-o-Y May 27, 2019 12:57 PM IST

    Suven Life Sci Standalone March 2019 Net Sales at Rs 253.30 crore, up 18.52% Y-o-Y

  • Suven Life gets product patents in Eurasia, Europe, South Korea and Sri Lanka Mar 29, 2019 11:33 AM IST

    Suven Life gets product patents in Eurasia, Europe, South Korea and Sri Lanka

    The granted claims of patents are being developed as therapeutic agents useful in treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder, Huntington's disease, Parkinson's and schizophrenia, it added.

  • Suven plans to buy US-based Rising Pharmaceuticals' assets Mar 08, 2019 10:55 AM IST

    Suven plans to buy US-based Rising Pharmaceuticals' assets

    Suven Life Sciences through its joint venture partner, Shore Suven Pharma, Inc has entered into a "stalking-horse" asset purchase agreement to buy the assets of Aceto Corporation's Rising Pharmaceuticals and Rising subsidiaries, Suven Life said in a regulatory filing.

  • Suven Life Sciences rises 2% after JV acquires bankrupt Rising Pharmaceuticals in US Mar 08, 2019 09:40 AM IST

    Suven Life Sciences rises 2% after JV acquires bankrupt Rising Pharmaceuticals in US

    "This potential acquisition of Rising's assets would transform Shore Suven Pharma into a strong US generic pharmaceutical company," Venkat Jasti, CEO & Chairman of Suven Life Sciences said.

  • Suven Life Sci Standalone December 2018 Net Sales at Rs 129.02 crore, down 21.16% Y-o-Y Feb 06, 2019 10:55 AM IST

    Suven Life Sci Standalone December 2018 Net Sales at Rs 129.02 crore, down 21.16% Y-o-Y

  • Suven Life Sciences gains 3% on product patents in Brazil and Eurasia Dec 27, 2018 11:29 AM IST

    Suven Life Sciences gains 3% on product patents in Brazil and Eurasia

    These two patents are valid through 2023 and 2034 respectively.

  • Suven Life gets product patents from Brazil, Eurasia Dec 27, 2018 10:59 AM IST

    Suven Life gets product patents from Brazil, Eurasia

    These patents are valid through 2023 and 2034, respectively, the company said in a BSE filing.

Sections